Please note that LIDDS will disclose information in Press releases only in English going forward. Vänligen notera att LIDDS fortsättningsvis kommer att offentliggöra pressmeddelanden endast på engelska. Erik Penser temadag med bolag i cancerforskningens frontlinje, Stockholm, October 6, 2020, Monica Wallter, CEO LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months. Visitingadress: Virdings allé 32b, Uppsala LIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.comPress releases
Prostate cancer study to be initiated at Uppsala University Hospital with NanoZolid technology® International Journal of Pharmaceutics Publishes Study on the NanoZolid® Technology for Local Release of Biomolecules LIDDS CEO Interview with Finwire TV and Updated Company Presentation LIDDS updates on the Clinical Program for Liproca DepotEvents
Company Analysis
Photo Library
Video Library
Lidds
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.comSubscribe for news
Press releases
Prostate cancer study to be initiated at Uppsala University Hospital with NanoZolid technology® International Journal of Pharmaceutics Publishes Study on the NanoZolid® Technology for Local Release of Biomolecules LIDDS CEO Interview with Finwire TV and Updated Company Presentation LIDDS updates on the Clinical Program for Liproca Depot
press
KALLELSE TILL ÅRSSTÄMMA I LIDDS AB (publ)
events
analysis
